An association representing independent service organizations has challenged the plans of GE Medical Systems of Milwaukee to acquire equipment service provider InnoServ Technologies of Arlington, TX. The Independent Service Network International of
An association representing independent service organizations has challenged the plans of GE Medical Systems of Milwaukee to acquire equipment service provider InnoServ Technologies of Arlington, TX. The Independent Service Network International of Atlanta filed a public comment on Sept. 15 in a Washington, DC, federal court, taking issue with the deal just as GE claimed to have finalized the acquisition.
GE announced in April its plan to acquire InnoServ, which provides third-party service for a large number of GE scanners. The U.S. Department of Justice initially opposed the purchase, believing that the acquisition could reduce competition in the multivendor service market. The Justice Department dropped its opposition, however, after reaching a settlement with GE in which the company agreed to sell off InnoServs Prevu diagnostic software (SCAN 7/22/98).
GE on Sept. 16 reported that the boards of both companies had approved the deal and that the acquisition was complete. ISNI believes the companies may be moving too quickly, however. The acquisition still must be approved by the U.S. District Court for the District of Columbia, as is the case in all situations in which the federal government offers to settle an antitrust case, according to Ronald Katz, an attorney with Coudert Brothers in San Francisco. ISNI filed its challenge as part of the public comment requirements regarding the case.
ISNIs comment claims that selling Prevu is no solution for the loss of competition that will occur if the acquisition goes through, and asserts that the Justice Department has not provided enough information on the impact the deal will have on competition for multivendor service. The complaint asks the court to appoint a special master to more fully investigate the impact the deal would have on the market. Katz believes that the court could rule on the comments and pass judgment on the acquisition in the next several months.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.